Epidemiology of herpes simplex virus type 1 in Canada: systematic review, meta-analyses, and meta-regressions.
Canada
genital ulcer disease
herpes
meta-analysis
meta-regression
prevalence
seroprevalence
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2023
2023
Historique:
received:
07
12
2022
accepted:
23
06
2023
medline:
1
8
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
epublish
Résumé
The objective of this study was to characterize herpes simplex virus type 1 (HSV-1) epidemiology in Canada. HSV-1 publications as recent as December 6, 2021 were systematically reviewed, synthesized, and reported following PRISMA guidelines. Meta-analyses and meta-regressions were conducted. HSV-1 measures were extracted from 22 studies and included 32 overall seroprevalence measures (79 stratified), 2 overall proportions of HSV-1 detection in clinically diagnosed genital ulcer disease (2 stratified), and 8 overall proportions of HSV-1 detection in laboratory-confirmed genital herpes (27 stratified). Pooled mean seroprevalence was 19.1% [95% confidence interval (CI): 12.6-26.4%] among healthy children and 51.4% (95% CI: 47.3-55.5%) among healthy adults. Pooled mean seroprevalence among healthy general populations increased with age, with the lowest being 35.7% (95% CI: 29.1-42.6%) among individuals <20 years of age, and the highest being 70.0% (95% CI: 54.8-83.2) among individuals ≥40 years. Seroprevalence increased by 1.02-fold (95% CI: 1.01-1.04) per year. Pooled mean proportion of HSV-1 detection in genital ulcer disease was 30.8% (95% CI: 12.6-52.8%). Pooled mean proportion of HSV-1 detection in genital herpes was 37.4% (95% CI: 29.5-45.6%) and was highest in women and in young persons. Proportion of HSV-1 detection in genital herpes increased by 1.04-fold (95% CI: 1.00-1.08) per year. HSV-1 epidemiology in Canada appears to be shifting toward less oral acquisition in childhood and more genital acquisition in adulthood, particularly among youth. Both HSV-1 seroprevalence and proportion of HSV-1 detection in genital herpes are increasing with time.
Sections du résumé
Background
The objective of this study was to characterize herpes simplex virus type 1 (HSV-1) epidemiology in Canada.
Methods
HSV-1 publications as recent as December 6, 2021 were systematically reviewed, synthesized, and reported following PRISMA guidelines. Meta-analyses and meta-regressions were conducted.
Results
HSV-1 measures were extracted from 22 studies and included 32 overall seroprevalence measures (79 stratified), 2 overall proportions of HSV-1 detection in clinically diagnosed genital ulcer disease (2 stratified), and 8 overall proportions of HSV-1 detection in laboratory-confirmed genital herpes (27 stratified). Pooled mean seroprevalence was 19.1% [95% confidence interval (CI): 12.6-26.4%] among healthy children and 51.4% (95% CI: 47.3-55.5%) among healthy adults. Pooled mean seroprevalence among healthy general populations increased with age, with the lowest being 35.7% (95% CI: 29.1-42.6%) among individuals <20 years of age, and the highest being 70.0% (95% CI: 54.8-83.2) among individuals ≥40 years. Seroprevalence increased by 1.02-fold (95% CI: 1.01-1.04) per year. Pooled mean proportion of HSV-1 detection in genital ulcer disease was 30.8% (95% CI: 12.6-52.8%). Pooled mean proportion of HSV-1 detection in genital herpes was 37.4% (95% CI: 29.5-45.6%) and was highest in women and in young persons. Proportion of HSV-1 detection in genital herpes increased by 1.04-fold (95% CI: 1.00-1.08) per year.
Conclusions
HSV-1 epidemiology in Canada appears to be shifting toward less oral acquisition in childhood and more genital acquisition in adulthood, particularly among youth. Both HSV-1 seroprevalence and proportion of HSV-1 detection in genital herpes are increasing with time.
Identifiants
pubmed: 37521995
doi: 10.3389/fpubh.2023.1118249
pmc: PMC10375289
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1118249Informations de copyright
Copyright © 2023 AlMukdad, Harfouche, Farooqui, Aldos and Abu-Raddad.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet. 2007 Dec 22;370(9605):2127-37
pubmed: 18156035
PLoS One. 2019 Apr 22;14(4):e0215487
pubmed: 31009486
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Open Med. 2009;3(3):e123-30
pubmed: 21603045
J Infect. 2019 Oct;79(4):289-299
pubmed: 31376458
J Clin Microbiol. 1986 Dec;24(6):1093-7
pubmed: 3023439
Clin Infect Dis. 2013 Feb;56(3):352-3
pubmed: 23087393
JAMA. 2006 Aug 23;296(8):964-73
pubmed: 16926356
Best Pract Res Clin Obstet Gynaecol. 2014 Oct;28(7):1098-110
pubmed: 25153069
PLoS One. 2019 Jun 6;14(6):e0214151
pubmed: 31170140
Clin Infect Dis. 2018 Apr 3;66(8):1184-1191
pubmed: 29136161
Sci Rep. 2018 Jan 26;8(1):1661
pubmed: 29374178
Antiviral Res. 2004 Feb;61(2):73-81
pubmed: 14670580
N Engl J Med. 1997 Oct 16;337(16):1105-11
pubmed: 9329932
Res Synth Methods. 2019 Sep;10(3):476-483
pubmed: 30945438
Vaccine. 2014 Mar 20;32(14):1630-7
pubmed: 24480024
Sci Rep. 2019 Feb 4;9(1):1136
pubmed: 30718696
Sex Transm Dis. 2003 Oct;30(10):797-800
pubmed: 14520181
J Virol Methods. 1995 Nov;55(3):285-94
pubmed: 8609194
Clin Infect Dis. 2013 Aug;57(3):448-57
pubmed: 23572481
Sex Transm Dis. 2019 Dec;46(12):795-800
pubmed: 31764767
Sex Transm Dis. 2016 Dec;43(12):756-760
pubmed: 27835628
Epidemiol Infect. 2023 Feb 08;151:e33
pubmed: 36750224
BMC Med. 2019 Mar 11;17(1):57
pubmed: 30853029
NCHS Data Brief. 2018 Feb;(304):1-8
pubmed: 29442994
Sex Transm Infect. 2005 Jun;81(3):267-70
pubmed: 15923300
CNS Drugs. 2005;19(4):303-12
pubmed: 15813644
Ann Intern Med. 1991 Oct 1;115(7):520-6
pubmed: 1652909
Bull World Health Organ. 2020 May 01;98(5):315-329
pubmed: 32514197
EClinicalMedicine. 2021 May 07;35:100876
pubmed: 34027335
Epidemics. 2010 Dec;2(4):173-82
pubmed: 21352788
BMJ Glob Health. 2020 Jul;5(7):
pubmed: 32675066
Clin Microbiol Infect. 2004 Jun;10(6):530-6
pubmed: 15191381
Lancet Glob Health. 2019 Sep;7(9):e1197-e1225
pubmed: 31402004
N Engl J Med. 2016 Aug 18;375(7):666-74
pubmed: 27532832
Clin Infect Dis. 2013 Feb;56(3):344-51
pubmed: 23087395
Sex Transm Dis. 1993 Jul-Aug;20(4):230-5
pubmed: 8211541
Lancet Reg Health West Pac. 2021 Jun 09;12:100176
pubmed: 34527970
Sex Transm Infect. 2021 Nov;97(7):490-500
pubmed: 34088792
Vaccine. 2016 Jun 3;34(26):2939-2947
pubmed: 27105564
Sex Transm Dis. 2022 Jun 1;49(6):403-413
pubmed: 35608096
Herpes. 2002 Jul;9(2):38-45
pubmed: 12106510
Open Forum Infect Dis. 2021 Apr 29;8(7):ofab218
pubmed: 34262986
J Am Acad Dermatol. 2007 Nov;57(5):737-63; quiz 764-6
pubmed: 17939933
Clin Infect Dis. 2019 Feb 15;68(5):757-772
pubmed: 30020453
Can J Public Health. 2011 May-Jun;102(3):225-9
pubmed: 21714324
J Obstet Gynecol Neonatal Nurs. 2009 May-Jun;38(3):320-6
pubmed: 19538620